He also said he has been able to stop taking insulin.
Pritzker described the results as life-changing, saying he feels “a whole lot different and a whole lot better.” CBS reported that the governor lost about two pounds during his first week using the medication, although Pritzker emphasized that his overall transformation did not happen overnight.
But another portion of the interview raises a much broader question—one involving Illinois taxpayers.
Pritzker disclosed that the state’s employee health insurance program covers GLP-1 medications for approximately 55,000 state employees.
“Why? We’re going to save money,” he said.
The governor argued that the medications could ultimately reduce healthcare costs by helping people lose weight and lowering the incidence of diabetes and other obesity-related conditions.
That argument is not simply theoretical policy talk. Illinois formally expanded GLP-1 coverage under its State Employees Group Insurance Program beginning July 1, 2024. State health plans are required to cover medically necessary injectable medications prescribed to improve glucose control or promote weight loss for adults diagnosed with obesity, prediabetes or gestational diabetes, subject to program requirements.
The price tag, however, immediately became part of the debate.
When the expanded coverage was announced, Pritzker’s administration estimated that the first full year could cost approximately $210 million. Outside analysts warned that the actual expense could be substantially greater. One economic analysis cited by WBEZ estimated that the net cost could potentially reach hundreds of millions of dollars depending on participation and drug costs.
That makes Pritzker’s new disclosure especially notable.
The governor personally has considerable financial resources. Current estimates place his net worth at approximately $4.2 billion, with his wealth stemming from the Pritzker family fortune and investments.
That does not establish that Pritzker personally receives his medication through the Illinois state employee insurance program. CBS did not report that he does, and the available reporting does not establish that his prescriptions are being paid for by Illinois taxpayers.
That distinction matters.
What is clear is that Pritzker is publicly promoting the same class of medications that Illinois made available through its state employee health program while simultaneously arguing that the program can save taxpayers money over the long term.
The governor has also rejected the idea that his weight loss was primarily motivated by presidential ambitions.
When CBS asked whether his transformation was connected to a potential 2028 White House campaign, Pritzker said he had wanted to lose weight throughout his life.
“I’ve been driven my whole life to lose weight.”
He added that the availability of GLP-1 medication finally gave him an option that worked for him.
Pritzker has not ruled out a future presidential bid, but he said his immediate focus remains Illinois. Asked specifically about 2028, he responded that he is concentrating on what is best for the people of the state and said he wants to remain governor “for a while longer.”
There is also an important piece of context surrounding the state program.
Illinois’ official benefits information requires members receiving an initial prescription for qualifying weight-loss medication to participate in a lifestyle management program. Failure to enroll or continue participating can result in future coverage being denied.
Supporters of the policy argue that paying for treatment now could reduce expensive medical problems later. Critics, however, have questioned whether the upfront costs will actually be offset by future savings.
That debate was already underway when the coverage expansion was approved.
In 2024, WBEZ reported that an economist’s analysis suggested the state’s costs could be far higher than the administration’s $210 million projection under certain participation scenarios. The analysis estimated costs could reach more than $461 million, with even higher gross expenditures possible before accounting for potential healthcare savings.
That leaves Illinois taxpayers with a straightforward question: What has the program actually cost, and how much has it saved?
Pritzker’s latest comments make that question even more relevant.
If the state’s investment in GLP-1 drugs is producing substantial reductions in diabetes, obesity-related illnesses and other medical expenses, Illinois taxpayers deserve to see the numbers.
And if the program is costing substantially more than anticipated, they deserve to know that as well.
Pritzker’s personal experience may be compelling. His 80-pound weight loss is certainly a significant change, and he has openly credited the medication with helping him achieve it.
But a governor’s personal success with a prescription drug and the fiscal performance of a massive state healthcare program are two different questions.
Illinois residents can applaud the governor’s health transformation while still demanding transparency about the billions of dollars moving through the state’s healthcare system.
The real test for the taxpayer-funded GLP-1 program will not be how much weight Pritzker lost.
It will be whether the promised savings actually appear in Illinois’ books.
